Immunotech Biopharm (HKSE:06978) ROCE % : -39.66% (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Immunotech Biopharm ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Immunotech Biopharm's annualized ROCE % for the quarter that ended in Jun. 2024 was -39.66%.

Immunotech Biopharm ROCE % Historical Data

The historical data trend for Immunotech Biopharm's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunotech Biopharm ROCE % Chart

Immunotech Biopharm Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-44.91

-63.46

-34.09

-37.56

-49.25

Immunotech Biopharm Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial							-31.50	-46.31	-29.51	-56.50	-39.66

Immunotech Biopharm ROCE % Calculation

Immunotech Biopharm's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-357.622	/	( ( (982.08 - 232.806)	+	(925.648 - 222.514) )	/ 2 )
	=	-357.622	/	( (749.274	+	703.134)	/ 2 )
	=	-357.622	/	726.204
	=	-49.25 %

Immunotech Biopharm's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-190.99	/	( ( (925.648 - 222.514)	+	(774.809 - 514.81) )	/ 2 )
	=	-190.99	/	( ( 703.134	+	259.999 )	/ 2 )
	=	-190.99	/	481.5665
	=	-39.66 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Immunotech Biopharm (HKSE:06978) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Immunotech Biopharm ROCE % Related Terms

Thank you for viewing the detailed overview of Immunotech Biopharm's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunotech Biopharm Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunotech Biopharm Ltd (HKSE:06978) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176

Website

https://www.eaal.net

Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.

Executives

Jung Hyun Chul
Evodevo Ltd
Tian Jin He Yue Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo	2501 Other
Wu Naifeng	2501 Other
Yan Kaijing	2501 Other
Yan Xijun	2501 Other
Tian Shi Li Kong Gu Ji Tuan You Xian Gong Si	2501 Other
Tian Shi Li Yi Yao Ji Tuan Gu Fen You Xian Gong Si	2501 Other
Tian Jin Di Zhi Tou Zi Guan Li You Xian Gong Si	2501 Other
Tian Jin Fu Hua De Ke Ji Kai Fa You Xian Gong Si	2501 Other
Li Yunhui	2501 Other
Tian Jin Hong Xun Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo	2501 Other
Tian Jin Kang Shun Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo	2501 Other
Tian Jin Shan Zhen Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo	2501 Other
Tian Jin Shun Qi Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo	2501 Other

Immunotech Biopharm Headlines

No Headlines